

## **Boston Scientific Announces Schedule of Events at TCT Conference**

(September 22, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C., which runs from September 27 through October 1. Boston Scientific will be announcing broad-based data on its TAXUS™ Express<sup>2</sup>™ paclitaxel-eluting stent system, including results from the TAXUS II, IV and V clinical trials, as well as data from the ARRIVE, Milestone II and WISDOM "real-world" registries. Together, these studies represent more than 10,000 patients. The TAXUS clinical trials represent the largest body of randomized drug-eluting stent data available today. Boston Scientific's participation in TCT 2004 will include 21 clinical abstracts and 56 additional scientific presentations. The Company will also highlight its simulation training programs for clinicians, including two of its mobile training buses.

### **Schedule of major events (all times are ET)**

Wednesday, September 29:

- **TAXUS II Two-Year Results:** At 9:30 a.m., highlights of the results will be provided at a press conference for credentialed media hosted by TCT in Room 158-AB of the new Washington Convention Center, 801 Mount Vernon Place NW, Washington, D.C. The information provided at the press conference will be embargoed until 11:00 a.m. when the results will be presented by Antonio Colombo, M.D., the study's Principal Investigator, at a scientific session scheduled to take place at that time in the Main Arena, Hall D of the Convention Center. The Company will issue a press release at 11:00 a.m., and the presentation will be simultaneously webcast by the symposium's sponsor. To register for the webcast, visit [www.tctmd.com](http://www.tctmd.com).
- **TAXUS IV Two-Year Results:** At 9:45 a.m., highlights of the results will be provided at a press conference for credentialed media hosted by TCT in Room 158-AB of the Convention Center. The information provided at the press conference will be embargoed until 11:15 a.m. when the results will be presented by Gregg W. Stone, M.D., the study's Co-Principal Investigator, at a scientific session scheduled to take place at that time in the Main Arena, Hall D of the Convention Center. The Company will issue a press release at 11:15 a.m., and the presentation will be simultaneously webcast by the symposium's sponsor. To register for the webcast, visit [www.tctmd.com](http://www.tctmd.com).
- **Analyst meeting:** At 5:30 p.m., the Company will host an analyst meeting in Congressional Hall B of the Renaissance Hotel, 999 Ninth St. NW, Washington, D.C. The meeting is open to the media. This meeting is being webcast and can be accessed at Boston Scientific's website, [www.bostonscientific.com](http://www.bostonscientific.com). The webcast is also being distributed over CCBN's Investor Distribution Network via two locations: CCBN's Individual Investor Center [www.fulldisclosure.com](http://www.fulldisclosure.com), which is accessible to the public; and [www.streetevents.com](http://www.streetevents.com), CCBN's password-protected event management site for CCBN clients. A replay of the webcast will be archived and available for ten business days in the Webcast and Archives section of the Investor Relations site at [www.bostonscientific.com](http://www.bostonscientific.com) beginning at approximately 9:00 p.m. ET on September 29.
- **Symposium:** At 8:00 p.m., the Company will host a symposium entitled, "TAXUS -- Addressing Unanswered Questions: Shaping the Future of Drug-Eluting Stents," in the Grand Ballroom of the Renaissance Hotel. The Company will host a reception prior to the symposium from 7:00 to 8:00 p.m. outside the Grand Ballroom.

Friday, October 1:

- **ARRIVE, Milestone II and WISDOM Registry Results:** At 2:30 p.m., the Company will issue a press

release on combined registry data representing more than 7,000 patients, including more than 2,500 patients in its consecutive-enrollment ARRIVE peri-approval registry. The results will be presented by David Cox, M.D. and John Lasala, M.D., ARRIVE Principal Investigators, Kari Niemela, M.D., Milestone II Principal Investigator, and Alexandre Abizaid, M.D., WISDOM Principal Investigator, during the "TAXUS Clinical Trials Symposium" at the TCT "Drug-Eluting Stent Summit". The TAXUS symposium is scheduled to run from 2:00 - 4:00 p.m. Friday in Ballroom C of the Convention Center.

- **TAXUS V 30-Day Safety Data:** At 3:30 p.m., the Company will issue a press release on TAXUS V 30-day safety data. The results will be presented by Gregg W. Stone, M.D., the study's Principal Investigator, during the "TAXUS Clinical Trials Symposium" at the TCT "Drug-Eluting Stent Summit". The TAXUS symposium is scheduled to run from 2:00 - 4:00 p.m. Friday in Ballroom C of the Convention Center.

### **Simulation training opportunities**

Boston Scientific will also highlight a number of innovative simulation training opportunities for clinicians at TCT, featuring the Company's mobile simulation training units. Some of the hands-on simulation opportunities sponsored by the Company include:

- **FilterWire EZ™ Embolic Protection System:** One of the Boston Scientific mobile training units will be located at the Company's booth (No. 2758) in the Convention Center, and will feature simulation training on the use of the FilterWire EZ Embolic Protection System for the treatment of saphenous vein graft disease. A clinical specialist will be present to assist in practicing techniques and answering questions.
- **High-risk coronary lesions and carotid artery stenting:** A second mobile simulation training unit sponsored by Boston Scientific will be located at the Medical Simulation Corporation (MSC) booths, located in the TCT Education Center on the lower level of the Convention Center, and will feature training in high-risk coronary lesions, using a number of Boston Scientific technologies, as well as MSC's carotid artery stenting simulation training program.
- **TeachIVUS:** A new online image interpretation tool for clinicians, "TeachIVUS", will be available at the Company's booth and in the TCT Education Center. TeachIVUS was developed by John Hodgson, M.D., and is supported in part with a Boston Scientific grant.

Company representatives and physicians who helped develop the training programs will be available for interviews or comment. Members of the media are invited to visit the training units individually, or to attend the TCT-sponsored "Virtual Reality Medical Simulation Training Systems Media Tour" scheduled for Tuesday, September 28 at 6:00 p.m. (meet at the Press Room, Room 158-AB).

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: [www.bostonscientific.com](http://www.bostonscientific.com).

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, reimbursement policies, commercialization of new technologies, litigation, the Company's overall business strategy and other factors described in the Company's filings with the Securities and Exchange Commission.